Patients with relapsed/refractory CLL who received zanubrutinib achieved significantly superior PFS compared with ibrutinib. The prescribing information for Brukinsa ® (zanubrutinib) has been updated ...
HONG KONG, Jan. 6, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced that the National Medical Products Administration has approved a significant label update in China for its internally developed, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results